Alpha DNA Investment Management’s Bio-Techne TECH Stock Holding History

Alpha DNA Investment Management’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,624	Closed	-$631K	–	588
2021 Q1	$631K	Buy	+6,624	New	+$604K	0.73%	64

Other funds holding TECH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Alpha DNA Investment Management's TECH Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Bio-Techne (TECH) in Q2 2021, closing a stake of 6,624 shares — an estimated $631K sold.

Alpha DNA Investment Management first reported a position in TECH in Q1 2021 and held it in 1 quarter. The position peaked at $631K in Q1 2021. 511 funds tracked by Wall St. Rank hold TECH as of Q2 2021.

Alpha DNA Investment Management reported no remaining Bio-Techne position as of Q2 2021 after selling out during the quarter.
Alpha DNA Investment Management sold 6,624 Bio-Techne shares in Q2 2021, an estimated $631K.
Alpha DNA Investment Management first reported a position in Bio-Techne in Q1 2021 and held it in 1 quarter.
Alpha DNA Investment Management's Bio-Techne position peaked at $631K in Q1 2021.
511 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.